Cargando…

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports

RATIONALE: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. PATIENT CONCERNS: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chen, Liu, Song-Ran, Zhou, Shu, Li, Xiao-Hui, Wang, Xiao-Hui, Tao, Ya-Lan, Chang, Hui, Zhang, Wen-Wen, Li, Wen-Fei, Zhou, Si-Lang, Xia, Yun-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709293/
https://www.ncbi.nlm.nih.gov/pubmed/31393358
http://dx.doi.org/10.1097/MD.0000000000016592
_version_ 1783446176824033280
author Chen, Chen
Liu, Song-Ran
Zhou, Shu
Li, Xiao-Hui
Wang, Xiao-Hui
Tao, Ya-Lan
Chang, Hui
Zhang, Wen-Wen
Li, Wen-Fei
Zhou, Si-Lang
Xia, Yun-Fei
author_facet Chen, Chen
Liu, Song-Ran
Zhou, Shu
Li, Xiao-Hui
Wang, Xiao-Hui
Tao, Ya-Lan
Chang, Hui
Zhang, Wen-Wen
Li, Wen-Fei
Zhou, Si-Lang
Xia, Yun-Fei
author_sort Chen, Chen
collection PubMed
description RATIONALE: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. PATIENT CONCERNS: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. DIAGNOSIS: They were diagnosed as refractory nasopharyngeal carcinoma. INTERVENTIONS: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. OUTCOMES: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. LESSONS: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.
format Online
Article
Text
id pubmed-6709293
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67092932019-10-01 Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports Chen, Chen Liu, Song-Ran Zhou, Shu Li, Xiao-Hui Wang, Xiao-Hui Tao, Ya-Lan Chang, Hui Zhang, Wen-Wen Li, Wen-Fei Zhou, Si-Lang Xia, Yun-Fei Medicine (Baltimore) Research Article RATIONALE: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. PATIENT CONCERNS: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. DIAGNOSIS: They were diagnosed as refractory nasopharyngeal carcinoma. INTERVENTIONS: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. OUTCOMES: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. LESSONS: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma. Wolters Kluwer Health 2019-08-09 /pmc/articles/PMC6709293/ /pubmed/31393358 http://dx.doi.org/10.1097/MD.0000000000016592 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Chen, Chen
Liu, Song-Ran
Zhou, Shu
Li, Xiao-Hui
Wang, Xiao-Hui
Tao, Ya-Lan
Chang, Hui
Zhang, Wen-Wen
Li, Wen-Fei
Zhou, Si-Lang
Xia, Yun-Fei
Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title_full Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title_fullStr Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title_full_unstemmed Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title_short Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
title_sort recombined humanized endostatin (endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: three case reports
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709293/
https://www.ncbi.nlm.nih.gov/pubmed/31393358
http://dx.doi.org/10.1097/MD.0000000000016592
work_keys_str_mv AT chenchen recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT liusongran recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT zhoushu recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT lixiaohui recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT wangxiaohui recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT taoyalan recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT changhui recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT zhangwenwen recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT liwenfei recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT zhousilang recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports
AT xiayunfei recombinedhumanizedendostatinendostarintravenousinfusioninthetreatmentofrefractorynasopharyngealcarcinomathreecasereports